Novel aspects of immunosuppressive and radiotherapy management of Graves' ophthalmopathy.
Treatment of severe Graves' ophthalmopathy (GO) is a complex therapeutic challenge and, in spite of any efforts, about one third of patients are disappointed with the outcome of treatment. Glucocorticoids (GC), orbital radiotherapy (RT), or a combination of both, are most frequently used for their immunosuppressive effects. Novel immunosuppressive treatment procedures (or novel modalities of established treatments) are reviewed in the present article. GC has recently been used by the i.v. route and this treatment modality has been shown to be more effective and better tolerated than the oral route. Promising preliminary results have been reported by some authors with somatostatin analogs, octreotide and lanreotide. The number of patients treated so far is limited, most of the results have been obtained in nonrandomized or uncontrolled studies, and comparison with other validated methods of treatment is also needed. Because of the pathogenic role of cytokines, cytokine antagonists, currently evaluated in other autoimmune diseases, have been tested with positive results also in a small series of GO patients. The use of antioxidants might also be envisioned in the future, since in vitro studies have shown that oxygen free radicals might be involved in GO. Based on the shared antigen(s) theory, total thyroid ablation, by removing the bulk of shared antigens(s), might be beneficial for the course of GO. New data on recently performed placebo-controlled studies on orbital radiotherapy are discussed, together with studies on long-term safety of orbital radiotherapy.
Marcocci
C
C
Department of Endocrinology and Metabolism, University of Pisa, Pisa, Italy. c.marcocci@endoc.med.unipi.it
Marinò
M
M
Rocchi
R
R
Menconi
F
F
Morabito
E
E
Pinchera
A
A
D000975:Antioxidants / Q000627:therapeutic use; D016207:Cytokines / Q000037:antagonists & inhibitors; D006111:Graves Disease / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D006801:Humans; D007136:Immunoglobulins / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007167:Immunotherapy; D009915:Orbit / Q000473:pathology; D013004:Somatostatin / Q000502:physiology; D013965:Thyroidectomy
D000975:Antioxidants; D016207:Cytokines; D007136:Immunoglobulins; D007166:Immunosuppressive Agents; D013004:Somatostatin